Novartis' Systemic Mastocytosis Drug Positive In Phase II
Zacks Investment Research | Jul 01, 2016 04:43AM ET
Novartis AG (NYSE:NVS) announced that data from its phase II study, CPKC412D2201, on PKC412 (midostaurin) was published in The New England Journal of Medicine.
The open-label study enrolled adults (aged 18 years and above) who had the following subtypes of advanced systemic mastocytosis (SM) in the primary efficacy population – aggressive systemic mastocytosis, mast cell leukemia, and SM with an associated hematologic neoplasm. Patients enrolled in the trial received single-agent oral administration of PKC412 until disease progression or unacceptable toxicity.
Data demonstrated an overall response rate of 60% in patients suffering from SM. Results showed a median overall survival of 28.7 months, along with improvements in both bone marrow mast cell burden and serum tryptase levels.
We note that the FDA has recently granted Breakthrough Therapy designation to PKC412 for the treatment of adults with newly-diagnosed FLT3-mutated acute myeloid leukemia (AML). The candidate also enjoys Orphan Drug status in the EU and the U.S. for both AML and mastocytosis.
Advanced SM is rare and has a poor prognosis. As per the European Journal of Hematology, there is currently no approved treatment for the majority of patients suffering from the disease. Hence, the successful development and commercialization of PKC412 will bode well for Novartis.
We believe investors should look out for approval of new drugs and label expansion of existing ones at Novartis as the company has been facing stiff generic competition for some of its key drugs like Diovan and Gleevec. This apart, its oncology drugs are facing competition from immuno-oncology therapies. Moreover, its Alcon segment is witnessing a decline in surgical equipment sales in the U.S. and emerging markets.
Novartis currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the healthcare sector include Pfizer, Inc. (NYSE:PFE) , Bristol-Myers Squibb Co. (NYSE:BMY) and Johnson & Johnson (NYSE:JNJ) . While Pfizer and Bristol-Myers sport a Zacks Rank #1 (Strong Buy), Johnson & Johnson is a Zacks Rank #2 (Buy) stock.
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.